Flow Traders U.S.’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Flow Traders U.S.’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,427	Closed	–	–	1417
2024 Q3	$0	Sell	11,427 -4,586	-29%	-$140	﹤0.01%	1226
2024 Q2	$0	Buy	+16,013	New	+$1.02K	﹤0.01%	1161
2023 Q3	–	Sell	-10,837	Closed	-$1K	–	1229
2023 Q2	$1K	Buy	10,837 +114	+1%	+$9	﹤0.01%	819
2023 Q1	$0	Buy	+10,723	New	+$832	﹤0.01%	1167

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Flow Traders U.S.'s CLDI.WS Position: Q4 2024 in Review

Flow Traders U.S. sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 11,427 shares.

Flow Traders U.S. first reported a position in CLDI.WS in Q1 2023 and held it in 4 quarters. The position peaked at $1K in Q2 2023. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Flow Traders U.S. reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Flow Traders U.S. sold 11,427 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024.
Flow Traders U.S. first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2023 and held it in 4 quarters.
Flow Traders U.S.'s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $1K in Q2 2023.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Flow Traders U.S.'s 13F filing for Q4 2024, filed 14 Feb 2025.